Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/14/19
End: 07/14/22
Due: 07/14/23
Phase: N/A
Priority: Normal
Start: 12/20/23
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 10/09/23
End: 10/31/26
Due: 10/31/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects | NCT04165837 | 1ST Biotherapeutics, Inc. | user2@example.com | None | 2019-10-14 | 2022-07-14 | 2023-07-14 | - | - | 2025-07-14 |
| A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418 | NCT05995782 | 1ST Biotherapeutics, Inc. | user2@example.com | None | 2023-12-20 | 2024-12-31 | 2025-12-31 | - | - | 2025-07-14 |
| A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 | NCT05761223 | 1ST Biotherapeutics, Inc. | user2@example.com | None | 2023-10-09 | 2026-10-31 | 2027-10-31 | - | - | 2025-07-14 |